-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 1, 2021, the Cancer Institute of the National University of Singapore (NCIS) and MiNA Therapeutics jointly announced that MiNA's small-activated RNA therapy MTL-CEBPA, combined with standard treatments atezolizumab and bevacizumab (bevacizumab), is the first-line treatment for advanced liver The phase 1 clinical trial for patients with cell carcinoma (HCC) has completed the first patient's administration
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths worldwide
The phenomenon that can specifically up-regulate targeted genes is called RNA activation (RNAa), and those small double-stranded RNAs with RNAa function are called small activating RNA (saRNA)
The press release pointed out that MTL-CEBPA is the first therapy to specifically upregulate CCAAT/enhancer binding protein alpha (C/EBP-α).
The open-label Phase 1 trial will enroll approximately 30 patients with unresectable or advanced HCC who have not received systemic therapy in the past
Reference materials:
[1] National University Cancer Institute, Singapore and MiNA Therapeutics Announce Initiation of a Phase 1 Clinical Study of MTL-CEBPA in Combination With First-line Standard of Care in Advanced Liver Cancer.
(The original text has been deleted)
